Commission Implementing Decision (EU) 2018/945 of 22 June 2018 on the communicable diseases and related special health issues to be covered by epidemiological surveillance as well as relevant case definitions (Text with EEA relevance)

Article 1	The communicable diseases and related special health issues to be
Article 2	For the purposes of submitting data for the epidemiological surveillance
Article 3	Decisions 2000/96/EC and 2002/253/EC are hereby repealed. References to those
Article 4	This Decision shall enter into force on the 20th day Signature
	-

ANNEX I

Communicable diseases and related special health issues to be covered by the epidemiological surveillance network

- 1. DISEASES
- 2. SPECIAL HEALTH ISSUES

ANNEX II

1. EXPLANATION OF THE SECTIONS USED IN THE DEFINITION AND CLASSIFICATION...

CLINICAL CRITERIA

LABORATORY CRITERIA

EPIDEMIOLOGICAL CRITERIA AND EPIDEMIOLOGICAL LINK

CASE CLASSIFICATION

POSSIBLE CASE

PROBABLE CASE

CONFIRMED CASE

LABORATORY-CONFIRMED CASE WITH CLINICAL CRITERIA

LABORATORY-CONFIRMED CASE WITH UNKNOWN CLINICAL

CRITERIA

LABORATORY-CONFIRMED CASE WITHOUT CLINICAL CRITERIA

- 2. ABBREVIATION LIST
- 3. CASE DEFINITIONS OF COMMUNICABLE DISEASES
 - 3.1. ANTHRAX

Clinical Criteria Laboratory Criteria Epidemiological Criteria Status: Point in time view as at 22/06/2018.

Changes to legislation: There are currently no known outstanding effects for the Commission Implementing Decision (EU) 2018/945. (See end of Document for details)

Case Classification

3.2. BOTULISM

Clinical Criteria

Laboratory Criteria

Epidemiological Criteria

Case Classification

3.3. BRUCELLOSIS

Clinical Criteria

Laboratory Criteria

Epidemiological Criteria

Case Classification

3.4. CAMPYLOBACTER ENTERITIS

Clinical Criteria

Laboratory Criteria

Epidemiological Criteria

Case Classification

Antimicrobial resistance

3.5. CHIKUNGUNYA VIRUS DISEASE

Clinical Criteria

Laboratory Criteria

A. Probable case

B. Confirmed case

Epidemiological Criteria

Case Classification

3.6. CHLAMYDIAL INFECTION, INCLUDING CHLAMYDIAL

LYMPHOGRANULOMA (VENEREUM) (LGV)

Clinical Criteria

Laboratory Criteria

Chlamydial infection non-LGV

LGV

Epidemiological Criteria

Case Classification

3.7. CHOLERA

Clinical Criteria

Laboratory Criteria

Epidemiological Criteria

Case Classification

3.8. CREUTZFELDT-JAKOB DISEASE (CJD)

Preconditions

Clinical Criteria

Diagnostic Criteria

Diagnostic criteria for case confirmation:

Diagnostic criteria for a probable or a possible case:

Epidemiological Criteria

Case Classification

3.9. CRYPTOSPORIDIOSIS

Clinical Criteria

Laboratory Criteria

Epidemiological Criteria

Case Classification

3.10. DENGUE

Clinical Criteria

Laboratory Criteria

Status: Point in time view as at 22/06/2018.

Changes to legislation: There are currently no known outstanding effects for the Commission Implementing Decision (EU) 2018/945. (See end of Document for details)

A. Probable case

B. Confirmed case

Epidemiological Criteria

Case Classification

3 11 DIPHTHERIA

Clinical Criteria

Laboratory Criteria

Epidemiological Criteria

Case Classification

3.12. ECHINOCOCCOSIS

Clinical Criteria

Diagnostic Criteria

Case Classification

3.13. GIARDIASIS (LAMBLIASIS)

Clinical Criteria

Laboratory Criteria

Epidemiological Criteria

Case Classification

3.14. GONOCOCCAL INFECTION

Clinical Criteria

Laboratory Criteria

Epidemiological Criteria

Case Classification

Antimicrobial resistance

3.15. HAEMOPHILUS INFLUENZAE INFECTION, INVASIVE DISEASE

Clinical Criteria

Laboratory Criteria

Case Classification

3.16. ACUTE HEPATITIS A

Clinical Criteria

Laboratory Criteria

Epidemiological Criteria

Case Classification

3.17. HEPATITIS B

Clinical Criteria

Laboratory Criteria

Epidemiological Criteria

Case Classification

3.18. HEPATITIS C

Clinical Criteria

Laboratory Criteria

Case Classification

3.19. HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION AND ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)...

Clinical Criteria (AIDS)

Laboratory Criteria (HIV)

Case Classification

3.20. INFLUENZA

Clinical Criteria

Laboratory Criteria

Epidemiological Criteria

Case Classification

3.21. INFLUENZA A/H5N1

and related special...

Document Generated: 2023-12-14

Status: Point in time view as at 22/06/2018.

Changes to legislation: There are currently no known outstanding effects for the Commission Implementing Decision (EU) 2018/945. (See end of Document for details)

Clinical Criteria

Laboratory Criteria

Epidemiological Criteria

Case Classification

3 22 LEGIONNAIRES' DISEASE

Clinical Criteria

Laboratory Criteria

Laboratory criteria for case confirmation

Laboratory criteria for a probable case

Case Classification

3.23. LEPTOSPIROSIS

Clinical Criteria

Laboratory Criteria

Epidemiological Criteria

Case Classification

3 24 LISTERIOSIS

Clinical Criteria

Listeriosis in pregnancy:

Laboratory Criteria

Epidemiological Criteria

Case Classification

3.25. LYME NEUROBORRELIOSIS

Clinical Criteria

Laboratory Criteria

A. Confirmed case

B. Probable case

Epidemiological Criteria

Case Classification

3.26. MALARIA

Clinical Criteria

Laboratory Criteria

Case Classification

3.27. MEASLES

Clinical Criteria

Laboratory Criteria

Epidemiological criteria

Case Classification

3.28. MENINGOCOCCAL INFECTION, INVASIVE DISEASE

Clinical Criteria

Laboratory Criteria

Epidemiological Criteria

Case Classification

3.29. MUMPS

Clinical Criteria

Laboratory Criteria

Epidemiological Criteria

Case Classification

3.30. PERTUSSIS

Clinical Criteria

Notes:

Laboratory Criteria

Epidemiological Criteria

Case Classification

Status: Point in time view as at 22/06/2018.

Changes to legislation: There are currently no known outstanding effects for the Commission Implementing Decision (EU) 2018/945. (See end of Document for details)

3.31. PLAGUE

Clinical Criteria

Laboratory Criteria

Epidemiological Criteria

Case Classification

3.32. STREPTOCOCCUS PNEUMONIAE INFECTION, INVASIVE DISEASE

Clinical Criteria

Laboratory Criteria

Case Classification

Antimicrobial resistance:

3.33. ACUTE POLIOMYELITIS

Clinical Criteria

Laboratory Criteria

Epidemiological Criteria

Case Classification

3.34. Q FEVER

Clinical Criteria

Laboratory Criteria

Epidemiological Criteria

Case Classification

3.35. RABIES

Clinical Criteria

Laboratory Criteria

Epidemiological Criteria

Case Classification

3.36. RUBELLA

Clinical Criteria

Laboratory Criteria

Epidemiological Criteria

Case Classification

3.37. CONGENITAL RUBELLA SYNDROME

Clinical Criteria

Congenital rubella infection (CRI)

Congenital rubella syndrome (CRS)

Laboratory Criteria

Epidemiological Criteria

Case Classification Congenital Rubella

3.38. SALMONELLA ENTERITIS

Clinical Criteria

Laboratory Criteria

Epidemiological Criteria

Case Classification

Antimicrobial resistance

3.39. SEVERE ACUTE RESPIRATORY SYNDROME (SARS)

Clinical Criteria

Laboratory Criteria

Laboratory criteria for case confirmation

Laboratory criteria for a probable case

Epidemiological Criteria

Case Classification for the inter-epidemic period

Case Classification during an outbreak

Status: Point in time view as at 22/06/2018.

Changes to legislation: There are currently no known outstanding effects for the Commission Implementing Decision (EU) 2018/945. (See end of Document for details)

3.40. SHIGA TOXIN/VEROCYTOTOXIN-PRODUCING E. COLI INFECTION (STEC/VTEC), INCLUDING HAEMOLYTIC-URAEMIC SYNDROME (HUS)...

Clinical Criteria

STEC/VTEC diarrhoea

HUS

Laboratory Criteria

Epidemiological Criteria

Case Classification

3.41. SHIGELLOSIS

Clinical Criteria

Laboratory Criteria

Epidemiological Criteria

Case Classification

Antimicrobial resistance

3.42. SMALLPOX

Clinical Criteria

Laboratory Criteria

Laboratory criteria for case confirmation

Laboratory criteria for a probable case

Epidemiological Criteria

Case Classification

3.43. SYPHILIS

Clinical Criteria

Primary syphilis

Secondary syphilis

Early latent syphilis (< 1 year)

Laboratory Criteria

Epidemiological Criteria

Primary/secondary syphilis

Early latent syphilis

Case Classification

3.44. CONGENITAL SYPHILIS

Clinical Criteria

Laboratory Criteria

Laboratory criteria for case confirmation

Laboratory criteria for a probable case

Epidemiological Criteria

Case Classification

3.45. TETANUS

Clinical Criteria

Case Classification

3.46. TICK-BORNE VIRAL ENCEPHALITIS

Clinical Criteria

Laboratory Criteria

Laboratory criteria for case confirmation:

Laboratory criteria for a probable case:

Epidemiological Criteria

Case Classification

3.47. CONGENITAL TOXOPLASMOSIS

Clinical Criteria

Laboratory Criteria

Case Classification

Status: Point in time view as at 22/06/2018.

Changes to legislation: There are currently no known outstanding effects for the Commission Implementing Decision (EU) 2018/945. (See end of Document for details)

3.48. TRICHINELLOSIS

Clinical Criteria

Laboratory Criteria

Epidemiological Criteria

Case Classification

3.49. TUBERCULOSIS

Clinical Criteria

Laboratory Criteria

Laboratory criteria for case confirmation

Laboratory criteria for a probable case

Case Classification

Antimicrobial resistance

3.50. TULARAEMIA

Clinical Criteria

Laboratory Criteria

Epidemiological Criteria

Case Classification

3.51. TYPHOID AND PARATYPHOID FEVERS

Clinical Criteria

Laboratory Criteria

Epidemiological Criteria

Case Classification

3.52. VIRAL HAEMORRHAGIC FEVERS (VHF)

Clinical Criteria

Laboratory Criteria

Epidemiological Criteria

Case Classification

3.53. WEST NILE VIRUS INFECTION (WNV)

Clinical Criteria

Laboratory Criteria

Laboratory test for case confirmation

Laboratory test for a probable case

Epidemiological Criteria

Case Classification

3.54. YELLOW FEVER

Clinical Criteria

Laboratory Criteria

Epidemiological Criteria

Case Classification

3.55. ENTERITIS DUE TO YERSINIA ENTEROCOLITICA OR YERSINIA PSEUDOTUBERCULOSIS

Clinical Criteria

Laboratory Criteria

Epidemiological Criteria

Case Classification

3.56. ZIKA VIRUS DISEASE

Clinical Criteria

Laboratory Criteria

A. Confirmed case

B. Probable case

Epidemiological Criteria

Case Classification

3.57. CONGENITAL ZIKA VIRUS DISEASE

Status: Point in time view as at 22/06/2018.

Changes to legislation: There are currently no known outstanding effects for the Commission Implementing Decision (EU) 2018/945. (See end of Document for details)

Clinical Criteria
Laboratory Criteria
A. Confirmed case
Epidemiological Criteria
Case Classification

4. CASE DEFINITIONS OF SPECIAL HEALTH ISSUES

4.1. GENERAL CASE DEFINITION OF NOSOCOMIAL INFECTION (OR 'HEALTHCARE-ASSOCIATED INFECTION (HAI)')...

4.1.1. BJ: Bone and joint infection

BJ-BONE: Osteomyelitis

Note reporting instruction

BJ-JNT: Joint or bursa

BJ-DISC: Disc space infection

4.1.2. BSI: Bloodstream infection

BSI: Laboratory-confirmed bloodstream infection

4.1.3. CNS: Central nervous system infection

CNS-IC: Intracranial infection (brain abscess, subdural or epidural infection, encephalitis)...

Note reporting instruction

CNS-MEN: Meningitis or ventriculitis

Note reporting instructions

CNS-SA: Spinal abscess without meningitis

Note reporting instruction

4.1.4. CRI: Catheter-related infection

CRI1-CVC: Local CVC-related infection (no positive blood culture)

CRI1-PVC: Local PVC-related infection (no positive blood culture)

CRI2-CVC: General CVC-related infection (no positive blood culture)

CRI2-PVC: General PVC-related infection (no positive blood

culture)

CP12 CVC: migraphialogically confirmed CVC related

CRI3-CVC: microbiologically confirmed CVC-related

bloodstream infection

CRI3-PVC: microbiologically confirmed PVC-related bloodstream infection

4.1.5. CVS: Cardiovascular system infection

CVS-VASC: Arterial or venous infection

Note reporting instructions

CVS-ENDO: Endocarditis

CVS-CARD: Myocarditis or pericarditis

CVS-MED: Mediastinitis

Note reporting instruction

4.1.6. EENT: Eye, ear, nose, throat, or mouth infection

EENT-CONJ: Conjunctivitis

Note reporting instructions

EENT-EYE: Eye, other than conjunctivitis

EENT-EAR: Ear mastoid

EENT-ORAL: Oral cavity (mouth, tongue, or gums)

Note reporting instruction

EENT-SINU: Sinusitis

Status: Point in time view as at 22/06/2018.

Changes to legislation: There are currently no known outstanding effects for the Commission Implementing Decision (EU) 2018/945. (See end of Document for details)

EENT-UR: Upper respiratory tract, pharyngitis, laryngitis, epiglottitis

4.1.7. GI: Gastrointestinal system infection

GI-CDI: Clostridium difficile infection

GI-GE: Gastroenteritis (excl. CDI)

GI-GIT: Gastrointestinal tract (esophagus, stomach, small and large bowel, and...

GI-HEP: Hepatitis

Note reporting instructions

GI-IAB: Intraabdominal, not specified elsewhere including gallbladder, bile ducts, liver...

Note reporting instruction

4.1.8. LRI: Lower respiratory tract infection, other than pneumonia

LRI-BRON: Bronchitis, tracheobronchitis, bronchiolitis, tracheitis, without evidence of pneumonia

Note reporting instruction

LRI-LUNG: Other infections of the lower respiratory tract

Note reporting instruction

4.1.9. NEO: Specific neonatal case definitions

NEO-CSEP: Clinical Sepsis

NEO-LCBI: Laboratory-confirmed BSI

Note reporting instructions

NEO-CNSB: Laboratory-confirmed BSI with coagulasenegative staphylococci

Note reporting instructions

NEO-PNEU: Pneumonia

NEO-NEC: Necrotising enterocolitis

4.1.10. PN: Pneumonia

Notes:

Intubation-associated pneumonia (IAP)

4.1.11. REPR: Reproductive tract infection

REPR-EMET: Endometritis

Note reporting instruction

REPR-EPIS: Episiotomy

REPR-VCUF: Vaginal cuff

Note reporting instruction

REPR-OREP: Other infections of the male or female reproductive tract...

Note reporting instructions

4.1.12. SSI: Surgical site infection

Superficial incisional (SSI-S)

Deep incisional (SSI-D)

Organ/Space (SSI-O)

4.1.13. SST: Skin and soft tissue infection

SST-SKIN: Skin infection

Note reporting instructions

SST-ST: Soft tissue (necrotizing fascitis, infectious gangrene, necrotizing cellulitis, infectious...

Note reporting instructions

SST-DECU: Decubitus ulcer, including both superficial and

deep infections SST-BURN: Burn

SST-BRST: Breast abscess or mastitis

and related special...

Document Generated: 2023-12-14

Status: Point in time view as at 22/06/2018.

Changes to legislation: There are currently no known outstanding effects for the Commission Implementing Decision (EU) 2018/945. (See end of Document for details)

4.1.14. SYS: Systemic infection

SYS-DI: Disseminated infection

Note reporting instructions

SYS-CSEP: treated unidentified severe infection

Note reporting instructions

4.1.15. UTI: Urinary tract infection

UTI-A: microbiologically confirmed symptomatic UTI

UTI-B: not microbiologically confirmed symptomatic UTI

4.2. GENERAL CASE DEFINITION OF BLOOD STREAM INFECTION DUE TO SPECIFIC...

Clinical criteria

Laboratory criteria

Epidemiological criteria

Case classification

Antimicrobial resistance

4.3. GENERIC CASE DEFINITION AND CLASSIFICATION OF ANTIMICROBIAL REISTANCE TO ANTIMICROBIAL...

Clinical resistance to antimicrobial agents

Definition

Classification

Clinically Susceptible (S)

Clinically Intermediate (I)

Clinically Resistant (R)

Pandrug-resistant (PDR)

Microbiological resistance to antimicrobial agents

Phenotypic definition

Phenotypic classification

Wild-type (WT) phenotype

Non-wild-type (NWT) phenotype

Identification of an acquired antimicrobial resistance mechanism (for example, drug...

Genotypic definition

Genotypic classification

Status: Point in time view as at 22/06/2018.

Changes to legislation: There are currently no known outstanding effects for the Commission Implementing Decision (EU) 2018/945. (See end of Document for details)

- (1) OJ L 293, 5.11.2013, p. 1.
- (2) Decision No 2119/98/EC of the European Parliament and of the Council of 24 September 1998 setting up a network for the epidemiological surveillance and control of communicable diseases in the Community (OJ L 268, 3.10.1998, p. 1).
- (3) Commission Decision 2000/96/EC of 22 December 1999 on the communicable diseases to be progressively covered by the Community network under Decision No 2119/98/EC of the European Parliament and of the Council (OJ L 28, 3.2.2000, p. 50).
- (4) Commission Decision 2002/253/EC of 19 March 2002 laying down case definitions for reporting communicable diseases to the Community network under Decision No 2119/98/EC of the European Parliament and of the Council (OJ L 86, 3.4.2002, p. 44).
- (5) Regulation (EC) No 851/2004 of the European Parliament and of the Council of 21 April 2004 establishing a European Centre for disease prevention and control (OJ L 142, 30.4.2004, p. 1).
- (6) Botulism, brucellosis, campylobacter enteritis, giardiasis, gonococcal infection, listeriosis, rubella, salmonella enteritis, shiga toxin/verocytotoxin-producing *E. coli* infection, shigellosis, syphilis and congenital syphilis, tetanus, tuberculosis, typhoid and paratyphoid fevers, pertussis, enteritis due to *Yersinia enterocolitica* or *Yersinia pseudotuberculosis* and healthcare-associated infections.
- (7) In general and, more specifically, campylobacter enteritis, gonococcal infection, salmonella enteritis, shigellosis, tuberculosis and bloodstream infections due to specific pathogens, in particular *Staphylococcus aureus* (susceptibility to meticillin and other anti-staphylococcal beta-lactams), *Enterococcus faecium* and *Enterococcus faecalis* (susceptibility to glycopeptides), *Klebsiella pneumoniae* and *Escherichia coli* (susceptibility to carbapenems and to colistin in carbapenem-resistant isolates), and *Pseudomonas aeruginosa* and *Acinetobacter* species (susceptibility to carbapenems).

Status:

Point in time view as at 22/06/2018.

Changes to legislation:

There are currently no known outstanding effects for the Commission Implementing Decision (EU) 2018/945.